NVO
Novo Nordisk A/S
NVO trails on the overall score without a compensating advantage in the available component scores.
RGEN
Repligen Corporation
RGEN has the edge over NVO overall, supported by stronger fundamentals and stronger modeled upside.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
RGEN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
RGEN's revenue, profitability, cash flow and balance sheet are all currently healthy.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
RGEN PE Valuation
RGEN has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
RGEN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Moderate |
RGEN has the edge over NVO on the outlook, with more favorable earnings expectations.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
RGEN has the stronger earnings trend. Trailing diluted EPS is up 4.9% for NVO versus RGEN up 38%.
RGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.43 | -16% |
| Q3 2022 | $2.90 | +38% |
| Q2 2022 | $2.77 | +55% |
| Q1 2022 | $2.53 | +74% |
| Q4 2021 | $2.24 | +102% |
| Q3 2021 | $2.10 | +156% |
| Q2 2021 | $1.79 | +209% |
| Q1 2021 | $1.45 | +222% |
| Q4 2020 | $1.11 | +152% |
RGEN's earnings per share have climbed steadily: $2.90 over the past year, up 38% from the year before, and higher year over year every quarter since late 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over RGEN on profitability, with a higher operating margin.
RGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $209.3M | +11% |
| Q2 2026 | $204.1M | +12% |
| Q1 2026 | $194.3M | +15% |
| Q4 2025 | $197.9M | +18% |
| Q3 2025 | $188.8M | +22% |
| Q2 2025 | $182.4M | +15% |
| Q1 2025 | $169.2M | +10% |
| Q4 2024 | $167.5M | +0.6% |
RGEN's revenue has grown year over year for nine quarters in a row: $209M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -14% | -23 points |
| Q2 2026 | 6.8% | -0.8 points |
| Q1 2026 | 8.2% | +4.3 points |
| Q4 2025 | 9% | +31 points |
| Q3 2025 | 8.9% | +14 points |
| Q2 2025 | 7.6% | +4.2 points |
| Q1 2025 | 3.9% | +1.4 points |
| Q4 2024 | -22% | -28 points |
RGEN's operating margin was −14% last quarter, down 23 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over RGEN on cash flow, with more consistent year-over-year improvement.
RGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $38.2M | -12% |
| Q2 2026 | $27.4M | +28% |
| Q1 2026 | $23.6M | +106% |
| Q4 2025 | $17.6M | -48% |
| Q3 2025 | $43.4M | +2.5% |
| Q2 2025 | $21.5M | -42% |
| Q1 2025 | $11.4M | -69% |
| Q4 2024 | $33.6M | +87% |
RGEN generated $107M in free cash flow over the past year, down 3% from the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has 4.4B diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
RGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -80K shares |
| 1 year | -1.4% | -810K shares |
RGEN has the edge over NVO on shareholder dilution, with a more favorable share count trend.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
RGEN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.8x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.3x | Net Cash |
| Q4 2025 | -0.2x | Net Cash |
| Q3 2025 | -2.7x | Net Cash |
| Q2 2025 | -14.0x | Net Cash |
| Q1 2025 | -17.8x | Net Cash |
| Q4 2024 | -21.9x | Net Cash |
RGEN has the edge over NVO on leverage, with a lower net debt burden relative to earnings.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
RGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 53.2 | Neutral |
| Stochastic | 48.9 | Neutral |
RGEN's weekly RSI is 53 (neutral) and its Stochastic is 49 (neutral).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RGEN PE vs Healthcare Sector
| Metric | RGEN | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RGEN has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
RGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $176.8 | 5.8% below |
| 20 week MA | $166.0 | 0.3% above |
| 50 week MA | $147.6 | 13% above |
| 100 week MA | $142.8 | 17% above |
| 200 week MA | $152.1 | 9.5% above |
RGEN has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
RGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $92.2 | $195.7 | +112% |
| 2021 | $195.7 | $264.7 | +35% |
| 2022 | $264.7 | $167.5 | -37% |
| 2023 | $167.5 | $179.8 | +7.3% |
| 2024 | $179.8 | $145.5 | -19% |
| 2025 | $145.5 | $166.2 | +14% |
| 2026 YTD | $166.2 | $166.5 | +0.2% |
RGEN has the edge over NVO on returns for 2026, with the stronger performance.